Figure 6.

Daily therapy of roniciclib and sorafenib in murine well-differentiated thyroid cancer xenograft tumor models. (A) Daily treatment of roniciclib (1.4 mg/kg) for 4 days significantly inhibited subcutaneous xenograft growth of K1 tumors compared with control mice on day 7. (B) Serial daily administration of roniciclib did not result in significant changes in body weight during the study period. (C) After FTC-133 flank tumors were established in nude mice, they were treated with oral gavage of placebo, roniciclib (1.4 mg/kg), sorafenib (25 mg/kg) or combination therapy once a day for three cycles of 4-day on and 3-day off therapy. Compared with control therapy, roniciclib, sorafenib and combination treatment all significantly inhibited tumor growth by day 3, and the inhibitory effects persisted through day 13. Combination therapy significantly retarded xenograft growth when compared with either single modality treatment on days 17 and 20. (D) No significant decreases in body weight were attributable to placebo, roniciclib, sorafenib or combination therapy compared with the baseline weight. Arrow, placebo, roniciclib, sorafenib and combination treatment.